8:25 am
Chair’s Opening Remarks

Recognizing the Clinical Impact of Myeloid Targeted Therapies to Benchmark Efficacy & Safety

8:30 am Industry Leaders’ Fireside Chat: Reviewing the Current Landscape & Future Potential of the Myeloid


  • Assessing the target landscape of myeloid-directed therapies to identify advances in well-known antigens and uncover the prospects of novel targets
  • Discussing the top challenges developers face and novel approaches to tackles these
  • Expressing opinions on combination therapies and the opportunity they create for myeloid-directed therapies
  • Securing safety and efficacy validation from clinical assets to reaffirm the potential of targeting the myeloid compartment

9:30 am Alligator’s CD40 Program


Targeting CD40 on Myeloid Cells to Reverse the Suppressive Tumor Microenvironment & Enhance T Cell Priming.

  • Mitazalimab, a second generation CD40 agonistic monoclonal antibody is currently under investigation in a phase 2 study in pancreatic cancer patients and have shown very promising Interim Results with ORR>50%
  • Preclinical data as well as clinical efficacy and pharmacodynamic biomarker data from the interim readout will be presented
  • Further, preclinical in vivo and vitro data on ATOR-4066, a third generation CD40 agonist, and a CD40xCEA bispecific antibody developed within the Neo-X-Prime™ platform will be presented

10:00 am How to Enhance Translatability of Myeloid-Targeted Therapies in Preclinical Models


  • Outlining BRGSF-HIS mice: Immunodeficient mice displaying functional human lymphoid and myeloid compartments, without GvHD and side effects
  • Examining myeloid cells functionality and assessing immune modulation induced by biologics in BRGSF-HIS model
  • Showcase of assessment of immune targeting agents in immune checkpoint humanized model

10:30 am
Morning Refreshment Break & Speed Networking

Harnessing the Power of Combination Therapies to Prime the Microenvironment & Prevent Therapy Resistance

11:30 am Targeting Tumor Microenvironment for Next Generation Cancer Immunotherapies

  • Darren Ji CEO, Elpiscience Biopharmaceuticals Inc.


  • A bispecific antibody targeting CD39/TGF-β to create an immune-friendly tumor microenvironment. Expected single agent activity in solid tumors
  • The bispecific macrophage engager (BiME®) brings and activates macrophages in the tumor proximity for a kill 

12:00 pm Round Table: Designing Rational Combinations to Improve Therapy Efficacy without Affecting Toxicity


  • Discussing best-practice to choose a targeted therapy to prime the tumor microenvironment and alleviate immunosuppression
  • Evaluating agents to activate the adaptive immune system and trigger tumor cell elimination
  • How can you determine the in vivo activity caused by each agent to demonstrate the enhanced impact of the combination approach?

12:30 pm
Lunch Break & Networking

1:30 pm First-In-Human Phase 1 Trial of IO-108, an Antagonist Antibody Targeting LILRB2 (ILT4), as Monotherapy & in Combination with Pembrolizumab in Adult Patients with Advanced Relapsed or Refractory Solid Tumors: Dose Escalation Data (NCT05054348)

  • Luke Chung Global Project Lead & Vice President - Clinical Development, Immune-Onc Therapeutics Inc.


  • IO-108 was well tolerated up to 1800 mg, both in monotherapy and in combination with pembrolizumab
  • Durable responses were observed in patients treated with IO-108 monotherapy and with IO-108 in combination with pembrolizumab
  • The encouraging data support further clinical development of IO-108 in patients with various advanced solid tumors

2:00 pm Preclinical Development of AB598, a CD39 Inhibitory Antibody, to Promote Anti-Tumor Immunity


  • AB598 is a potent and specific molecule capable of inhibiting CD39 in the TME
  • AB598 can activate myeloid cells by increasing the reservoir of extracellular ATP
  • Combining AB598 with chemotherapy in solid tumors is a promising approach for immuno-oncology

Utilizing Cell-Based & Direct Cell-Targeting Approaches to Drive a Strong Anti-Tumor Response

2:30 pm Employing a CAR-Macrophage to Mediate Directed Tumor Cell Killing

  • Thomas Condamine Vice President - Discovery & Translational Science, CARISMA Therapeutics Inc.


  • Engineering a CAR to boost specificity of macrophage cell therapy and mediate tumor cell phagocytosis
  • Retaining a pro-inflammatory cell phenotype to maintain tumor killing function
  • Boosting scalable manufacturing of autologous therapies to generate large numbers of targeted cells

3:00 pm
Afternoon Break & Refreshments

3:30 pm ACTM-838, a Novel Cell-Based Immunotherapy Enables Systemic Delivery with Tumor-Specific Effects & Generates Durable Anti-Tumor Immunity

  • Chan Whiting Chief Development Officer, Actym Therapeutics Inc.


  • STACT (S. Typhimurium-Attenuated Cancer Therapy) is a novel immunotherapeutic modality that can be systemically delivered with tumor-specific effects
  • Characteristics include: enriches in solid tumors, not healthy tissue, tumor-specific payload delivery and multiplexed targeting in a single therapy
  • ACTM-838 is Actym’s lead development candidate, a STACT that encodes engineered IL15 + eSTING payloads. ACTM-838 has potent single agent activity against multiple tumor models after IV dosing with synergy when combined with PD-1. ACTM-838 induces profound myeloid and broad immune reprogramming of the TME leading to anti-tumor immunological memory

4:00 pm Targeting Myeloid Derived Suppressor Cells (MDSCs) to Reshape the Immunosuppressive Microenvironment

  • Kamal Puri Chief Scientific Officer, Oncoresponse


  • Clarifying the various mechanisms of suppression by MDSCs to distinguish pathways for intervention Development of OR2805, a clinical stage anti-CD163 antibody derived from an Elite Responder to checkpoint inhibitor therapy that relieves immunosuppression caused by macrophages
  • Discovery of anti-LILRB2/ILT4 lead antibody OR502 that rescues T cells from macrophage-mediated suppression

4:30 pm ILT2 Blockade: Enhancing Immunotherapy Efficacy through Myeloid Cell Modulation


  • Enhances innate (myeloid, NK, NKT) and adaptive (CD8 T cell) immune activation
  • Potentiates FcγR, TLR and cGAS signaling
  • Demonstrates broad combination potential and improves CPI efficacy

5:00 pm Poster Session & Drinks Reception


This is the perfect opportunity to contribute to the conversation and share your cutting-edge research with this community while discovering exciting work carried out by your peers. Get in touch if you would like to be involved!

6:00 pm
Close of Conference Day One